Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis

Journal of Autoimmunity

Volumn 33, Issue 3-4, 2009, Pages 178-182

  Barak, V ^a   Selmi, C ^b   Schlesinger, M ^c   Blank, M ^d   Agmon Levin, N ^d   Kalickman, I ^a   Gershwin, M E ^f   Shoenfeld, Y ^d,e  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF MILAN   (Italy)

^c BARZILAI MEDICAL CENTER   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmune cholangitis; Cytokines; PBC; Serum markers; T regulatory cells

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; PROPERDIN; SOLUBLE INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHOLANGITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE MARKER; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; TREATMENT RESPONSE;

COMPLEMENT SYSTEM PROTEINS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIVER CIRRHOSIS, BILIARY; RECEPTORS, INTERLEUKIN-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 71649095850     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.09.010     Document Type: Article

References (49)

1. Kaplan M.M., and Gershwin M.E. Primary biliary cirrhosis. N Engl J Med 353 (2005) 1261-1273
2. Selmi C., Ichiki Y., Invernizzi P., Podda M., and Gershwin M.E. The enigma of primary biliary cirrhosis. Clin Rev Allergy Immunol 28 (2005) 73-81
3. Shoenfeld Y., Blank M., Abu-Shakra M., Amital H., Barzilai O., Berkun Y., et al. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases - 2008. Isr Med Assoc J 10 (2008) 13-19
4. Shoenfeld Y., Gilburd B., Abu-Shakra M., Amital H., Barzilai O., Berkun Y., et al. The mosaic of autoimmunity: genetic factors involved in autoimmune diseases - 2008. Isr Med Assoc J 10 (2008) 3-7
5. Iliffe G.D., Naidoo S., and Hunter T. Primary biliary cirrhosis associated with features of systemic lupus erythematosus. Dig Dis Sci 27 (1982) 274-278
6. Selmi C., Zuin M., and Gershwin M.E. The unfinished business of primary biliary cirrhosis. J Hepatol 49 (2008) 451-460
7. Gershwin M.E., Selmi C., Worman H.J., Gold E.B., Watnik M., Utts J., et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 42 (2005) 1194-1202
8. Gershwin M.E., Coppel R.L., and Mackay I.R. Primary biliary cirrhosis and mitochondrial autoantigens - insights from molecular biology. Hepatology 8 (1988) 147-151
9. Bjorkland A., Loof L., Mendel-Hartvig I., and Totterman T.H. Primary biliary cirrhosis. High proportions of B cells in blood and liver tissue produce anti-mitochondrial antibodies of several Ig classes. J Immunol 153 (1994) 2750-2757
10. Gershwin M.E., Ansari A.A., Mackay I.R., Nakanuma Y., Nishio A., Rowley M.J., et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 174 (2000) 210-225
11. Bjorkland A., Festin R., Mendel-Hartvig I., Nyberg A., Loof L., and Totterman T.H. Blood and liver-infiltrating lymphocytes in primary biliary cirrhosis: increase in activated T and natural killer cells and recruitment of primed memory T cells. Hepatology 13 (1991) 1106-1111
12. Krams S.M., Van de Water J., Coppel R.L., Esquivel C., Roberts J., Ansari A., et al. Analysis of hepatic T lymphocyte and immunoglobulin deposits in patients with primary biliary cirrhosis. Hepatology 12 (1990) 306-313
13. Schlesinger M., Benbassat C., and Shoenfeld Y. Complement profile in primary biliary cirrhosis. Immunol Res 11 (1992) 98-103
14. Tilg H., Wilmer A., Vogel W., Herold M., Nolchen B., Judmaier G., et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 103 (1992) 264-274
15. Witkowska A.M. Soluble ICAM-1: a marker of vascular inflammation and lifestyle. Cytokine 31 (2005) 127-134
16. Invernizzi P., Crosignani A., Battezzati P.M., Covini G., De Valle G., Larghi A., et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 25 (1997) 1090-1095
17. Barak V., Ginzburg M., Kalickman I., and Polliack A. Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 7 (1992) 431-438
18. Barak V., Nisman B., Dann E.J., Kalickman I., Ruchlemer R., Bennett M.A., et al. Serum interleukin 1 beta levels as a marker in hairy cell leukemia: correlation with disease status and sIL-2R levels. Leuk Lymphoma 14 Suppl. 1 (1994) 33-39
19. Ishibashi H., Nakamura M., Komori A., Migita K., and Shimoda S. Liver architecture, cell function, and disease. Semin Immunopathol (2009)
20. Kikuchi K., Lian Z.X., Yang G.X., Ansari A.A., Ikehara S., Kaplan M., et al. Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology 128 (2005) 304-312
21. Panzer S., Penner E., Nelson P.J., Prochazka E., Benda H., and Saurugger P.N. Identification of the platelet glycoprotein IIb/IIIa complex as a target antigen in primary biliary cirrhosis-associated autoimmune thrombocytopenia. Evidence that platelet-reactive autoantibodies can also bind to the mitochondrial antigen M2. J Autoimmun 3 (1990) 473-483
22. Wrenshall L.E., Smith D.R., Stevens E.T., and Miller J.D. Influence of interleukin-2 deficiency on the generation of autoimmune B cells. J Autoimmun 29 (2007) 125-133
23. Akkad D.A., Hoffjan S., Petrasch-Parwez E., Beygo J., Gold R., and Epplen J.T. Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. J Autoimmun 32 (2009) 110-115
24. Abe S., Narita R., Matsuhashi T., Oto T., Tabaru A., and Otsuki M. Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 20 (2008) 373-378
25. Barak V. Cytokine receptors in diseases. Israel J Med Sci 32 (1995) 19-24
26. Lan R.Y., Selmi C., and Gershwin M.E. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun 31 (2008) 7-12
27. Miller L.C., and Kaplan M.M. Serum interleukin-2 and tumor necrosis factor-alpha in primary biliary cirrhosis: decrease by colchicine and relationship to HLA-DR4. Am J Gastroenterol 87 (1992) 465-470
28. Mao T.K., Lian Z.X., Selmi C., Ichiki Y., Ashwood P., Ansari A.A., et al. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology 42 (2005) 802-808
29. Selmi C., Lleo A., Pasini S., Zuin M., and Gershwin M.E. Innate immunity and primary biliary cirrhosis. Curr Mol Med 9 (2009) 45-51
30. Yamano T., Higashi T., Nouso K., Nakatsukasa H., Kariyama K., Yumoto E., et al. Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosis. Clin Exp Immunol 122 (2000) 227-231
31. Kahaleh M.B., and LeRoy E.C. Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. Ann Intern Med 110 (1989) 446-450
32. Cavazzana I., Manuela N., Irene C., Barbara A., Sara S., Orietta B.M., et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?. J Autoimmun 28 (2007) 160-164
33. Hoshino A., Nagao T., Nagi-Miura N., Ohno N., Yasuhara M., Yamamoto K., et al. MPO-ANCA induces IL-17 production by activated neutrophils in vitro via classical complement pathway-dependent manner. J Autoimmun 31 (2008) 79-89
34. Katz Y., Revel M., and Strunk R.C. Interleukin 6 stimulates synthesis of complement proteins factor B and C3 in human skin fibroblasts. Eur J Immunol 19 (1989) 983-988
35. Feldmann M. Translating molecular insights in autoimmunity into effective therapy. Annu Rev Immunol 27 (2009) 1-27
36. Spadaro A., Scrivo R., Riccieri V., and Valesini G. Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis. Jt Bone Spine 75 (2008) 87-89
37. Altschuler E.L., and Kast R.E. Bupropion for fatigue and as a tumor necrosis factor-alpha lowering agent in primary biliary cirrhosis. Med Hypotheses 64 (2005) 118-119
38. Fracchia M., Secreto P., Tabone M., Zaffino C., Pera A., and Galatola G. Serum interferon gamma in primary biliary cirrhosis: effect of ursodeoxycholic acid and prednisone therapy alone and in combination. Eur J Gastroenterol Hepatol 12 (2000) 463-468
39. Neuman M., Angulo P., Malkiewicz I., Jorgensen R., Shear N., Dickson E.R., et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 17 (2002) 196-202
40. Binard A., Le Pottier L., Saraux A., Devauchelle-Pensec V., Pers J.O., and Youinou P. Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?. J Autoimmun 30 (2008) 63-67
41. Wang J., Wang G., Sun B., Li H., Mu L., Wang Q., et al. Interleukin-27 suppresses experimental autoimmune encephalomyelitis during bone marrow stromal cell treatment. J Autoimmun 30 (2008) 222-229
42. Liu Z., Jiu J., Liu S., Fa X., Li F., and Du Y. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion. J Autoimmun 29 (2007) 187-194
43. Nishikubo K., Imanaka-Yoshida K., Tamaki S., Hiroe M., Yoshida T., Adachi Y., et al. Th1-type immune responses by Toll-like receptor 4 signaling are required for the development of myocarditis in mice with BCG-induced myocarditis. J Autoimmun 29 (2007) 146-153
44. Vital E.M., and Emery P. The development of targeted therapies in rheumatoid arthritis. J Autoimmun 31 (2008) 219-227
45. Ueno Y., Moritoki Y., Shimosegawa T., and Gershwin M.E. Primary biliary cirrhosis: what we know and what we want to know about human PBC and spontaneous PBC mouse models. J Gastroenterol 42 (2007) 189-195
46. Whittingham S., Rowley M.J., and Gershwin M.E. A tribute to an outstanding immunologist - Ian Reay Mackay. J Autoimmun 31 (2008) 197-200
47. Gershwin M.E. Bone marrow transplantation, refractory autoimmunity and the contributions of Susumu Ikehara. J Autoimmun 30 (2008) 105-107
48. Blank M., and Gershwin M.E. Autoimmunity: from the mosaic to the kaleidoscope. J Autoimmun 30 (2008) 1-4
49. Shoenfeld Y., Selmi C., Zimlichman E., and Gershwin M.E. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmmun 31 (2008) 325-330